Company profile FDMT
After 39 days of this quarter the interest is at 110.0. Based on that we can calculate that during remaining 52 days it will total up to 257.0. 4D Molecular Therapeutics expected interest is significantly higher compared to previous quarter (+756.7%) and same quarter last year (+817.9%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 19 | 29 52.6% QoQ | 32 10.3% QoQ | 18 -43.8% QoQ |
| 2020 | 26 36.8% YoY 44.4% QoQ | 12 -58.6% YoY -53.8% QoQ | 23 -28.1% YoY 91.7% QoQ | 24 33.3% YoY 4.3% QoQ |
| 2021 | 24 -7.7% YoY 0.0% QoQ | 22 83.3% YoY -8.3% QoQ | 17 -26.1% YoY -22.7% QoQ | 22 -8.3% YoY 29.4% QoQ |
| 2022 | 26 8.3% YoY 18.2% QoQ | 44 100.0% YoY 69.2% QoQ | 26 52.9% YoY -40.9% QoQ | 40 81.8% YoY 53.8% QoQ |
| 2023 | 28 7.7% YoY -30.0% QoQ | 49 11.4% YoY 75.0% QoQ | 41 57.7% YoY -16.3% QoQ | 30 -25.0% YoY -26.8% QoQ |
| 2024 | 110 292.9% YoY 266.7% QoQ | - | - | - |
The average 5 years interest of 4D Molecular Therapeutics was 2.54 per week. The last year interest of 4D Molecular Therapeutics compared to the last 5 years has changed by 81.1%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 100.87%.
After 39 days of this quarter the interest is at 71.0. Based on that we can calculate that during remaining 52 days it will total up to 166.0. Genetic medicines expected interest is significantly lower compared to previous quarter (-55.7%) and same quarter last year (-58.8%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 66 | 191 189.4% QoQ | 197 3.1% QoQ | 156 -20.8% QoQ |
| 2020 | 370 460.6% YoY 137.2% QoQ | 232 21.5% YoY -37.3% QoQ | 151 -23.4% YoY -34.9% QoQ | 103 -34.0% YoY -31.8% QoQ |
| 2021 | 280 -24.3% YoY 171.8% QoQ | 227 -2.2% YoY -18.9% QoQ | 0 -100.0% YoY -100.0% QoQ | 140 35.9% YoY inf% QoQ |
| 2022 | 273 -2.5% YoY 95.0% QoQ | 220 -3.1% YoY -19.4% QoQ | 279 inf% YoY 26.8% QoQ | 241 72.1% YoY -13.6% QoQ |
| 2023 | 403 47.6% YoY 67.2% QoQ | 421 91.4% YoY 4.5% QoQ | 251 -10.0% YoY -40.4% QoQ | 375 55.6% YoY 49.4% QoQ |
| 2024 | 71 -82.4% YoY -81.1% QoQ | - | - | - |
The average 5 years interest of Genetic medicines was 17.8 per week. The last year interest of Genetic medicines compared to the last 5 years has changed by 42.3%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 66.1%.
After 39 days of this quarter the interest is at 108.0. Based on that we can calculate that during remaining 52 days it will total up to 252.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 126 | 146 15.9% QoQ | 169 15.8% QoQ | 141 -16.6% QoQ |
| 2020 | 347 175.4% YoY 146.1% QoQ | 217 48.6% YoY -37.5% QoQ | 262 55.0% YoY 20.7% QoQ | 221 56.7% YoY -15.6% QoQ |
| 2021 | 304 -12.4% YoY 37.6% QoQ | 339 56.2% YoY 11.5% QoQ | 131 -50.0% YoY -61.4% QoQ | 306 38.5% YoY 133.6% QoQ |
| 2022 | 424 39.5% YoY 38.6% QoQ | 285 -15.9% YoY -32.8% QoQ | 290 121.4% YoY 1.8% QoQ | 232 -24.2% YoY -20.0% QoQ |
| 2023 | 320 -24.5% YoY 37.9% QoQ | 483 69.5% YoY 50.9% QoQ | 244 -15.9% YoY -49.5% QoQ | 292 25.9% YoY 19.7% QoQ |
| 2024 | 108 -66.2% YoY -63.0% QoQ | - | - | - |
The average 5 years interest of Retinitis pigmentosa treatment was 20.64 per week. The last year interest of Retinitis pigmentosa treatment compared to the last 5 years has changed by 20.74%. The interest for Retinitis pigmentosa treatment is trending. The last year interest is quite higher compared to 5 years ago. It has increased by 59.03%.
There is not enough data for Choroideremia treatment to provide analysis
There is not enough data for Choroideremia treatment to provide correlation calculation
There is not enough data for Choroideremia treatment to provide analysis
There is not enough data for Fabry disease cardiomyopathy treatment to provide analysis
There is not enough data for Fabry disease cardiomyopathy treatment to provide correlation calculation
There is not enough data for Fabry disease cardiomyopathy treatment to provide analysis
There is not enough data for Wet age-related macular degeneration treatment to provide analysis
There is not enough data for Wet age-related macular degeneration treatment to provide correlation calculation
There is not enough data for Wet age-related macular degeneration treatment to provide analysis
After 34 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 58 days it will total up to 0.0. Diabetic macular edema treatment expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2018 | - | - | - | 70 |
| 2019 | 162 131.4% QoQ | 106 -34.6% QoQ | 120 13.2% QoQ | 119 70.0% YoY -0.8% QoQ |
| 2020 | 61 -62.3% YoY -48.7% QoQ | 51 -51.9% YoY -16.4% QoQ | 127 5.8% YoY 149.0% QoQ | 89 -25.2% YoY -29.9% QoQ |
| 2021 | 80 31.1% YoY -10.1% QoQ | 57 11.8% YoY -28.8% QoQ | 74 -41.7% YoY 29.8% QoQ | 314 252.8% YoY 324.3% QoQ |
| 2022 | 100 25.0% YoY -68.2% QoQ | 149 161.4% YoY 49.0% QoQ | 148 100.0% YoY -0.7% QoQ | 250 -20.4% YoY 68.9% QoQ |
| 2023 | 154 54.0% YoY -38.4% QoQ | 115 -22.8% YoY -25.3% QoQ | 98 -33.8% YoY -14.8% QoQ | 0 -100.0% YoY -100.0% QoQ |
The average 5 years interest of Diabetic macular edema treatment was 9.4 per week. The last year interest of Diabetic macular edema treatment compared to the last 5 years has changed by 10.43%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by -3.26%.
There is not enough data for Cystic fibrosis lung disease treatment to provide analysis
There is not enough data for Cystic fibrosis lung disease treatment to provide correlation calculation
There is not enough data for Cystic fibrosis lung disease treatment to provide analysis
After 39 days of this quarter the interest is at 100.0. Based on that we can calculate that during remaining 52 days it will total up to 233.0. Geographic atrophy treatment expected interest is significantly higher compared to previous quarter (+441.9%) and same quarter last year (+565.7%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 44 | 24 -45.5% QoQ | 10 -58.3% QoQ | 63 530.0% QoQ |
| 2020 | 41 -6.8% YoY -34.9% QoQ | 17 -29.2% YoY -58.5% QoQ | 29 190.0% YoY 70.6% QoQ | 27 -57.1% YoY -6.9% QoQ |
| 2021 | 8 -80.5% YoY -70.4% QoQ | 11 -35.3% YoY 37.5% QoQ | 57 96.6% YoY 418.2% QoQ | 82 203.7% YoY 43.9% QoQ |
| 2022 | 46 475.0% YoY -43.9% QoQ | 56 409.1% YoY 21.7% QoQ | 21 -63.2% YoY -62.5% QoQ | 21 -74.4% YoY 0.0% QoQ |
| 2023 | 35 -23.9% YoY 66.7% QoQ | 110 96.4% YoY 214.3% QoQ | 43 104.8% YoY -60.9% QoQ | 43 104.8% YoY 0.0% QoQ |
| 2024 | 100 185.7% YoY 132.6% QoQ | - | - | - |
The average 5 years interest of Geographic atrophy treatment was 3.4 per week. The last year interest of Geographic atrophy treatment compared to the last 5 years has changed by 84.41%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 113.27%.
There is not enough data for Alpha-1 antitrypsin deficiency lung disease treatment to provide analysis
There is not enough data for Alpha-1 antitrypsin deficiency lung disease treatment to provide correlation calculation
There is not enough data for Alpha-1 antitrypsin deficiency lung disease treatment to provide analysis